Adam E Gaweda
Overview
Explore the profile of Adam E Gaweda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lederer E, Sobh M, Brier M, Gaweda A
Clin Kidney J
. 2024 Jun;
17(6):sfae143.
PMID: 38899159
The global derangement of mineral metabolism that accompanies chronic kidney disease (CKD-MBD) is a major driver of the accelerated mortality for individuals with kidney disease. Advances in the delivery of...
2.
Gaweda A, Lederer E, Brier M
CPT Pharmacometrics Syst Pharmacol
. 2022 Aug;
11(10):1305-1315.
PMID: 35920131
Chronic kidney disease (CKD)-mineral bone disorder (MBD) is a complex clinical syndrome that begins early during CKD and evolves into one of the deadliest complications of CKD through its effects...
3.
Gaweda A, Lederer E, Brier M
Front Med (Lausanne)
. 2022 Apr;
9:807994.
PMID: 35402468
Chronic kidney disease (CKD) leads to clinically severe bone loss, resulting from the deranged mineral metabolism that accompanies CKD. Each individual patient presents a unique combination of risk factors, pathologies,...
4.
Gaweda A, McBride D, Lederer E, Brier M
Am J Physiol Renal Physiol
. 2020 Dec;
320(2):F203-F211.
PMID: 33308018
Chronic kidney disease mineral bone disorder (CKD-MBD) is a virtually universal complication of kidney diseases, starting early in the course of disease and resulting in devastating clinical consequences ranging from...
5.
Zheng Y, Merchant M, Burke T, Ritzenthaler J, Li M, Gaweda A, et al.
Oxid Med Cell Longev
. 2020 Jun;
2020:2468986.
PMID: 32587657
Slc7a11 is the key component of system X , an antiporter that imports cystine (CySS) and exports glutamate. It plays an important role in cellular defense against oxidative stress because...
6.
Agrawal S, Merchant M, Kino J, Li M, Wilkey D, Gaweda A, et al.
Kidney Int Rep
. 2020 Jan;
5(1):66-80.
PMID: 31922062
Introduction: Nephrotic syndrome (NS) is a characterized by massive proteinuria, edema, hypoalbuminemia, and dyslipidemia. Glucocorticoids (GCs), the primary therapy for >60 years, are ineffective in approximately 50% of adults and...
7.
Brier M, Gaweda A, Aronoff G
Semin Nephrol
. 2018 Aug;
38(4):410-417.
PMID: 30082060
Substantial progress has been made in the application of computer-driven methods to provide erythropoietic dosing information for patients with anemia resulting from chronic kidney disease. Initial solutions were simply computerized...
8.
Gaweda A, Jacobs A, Aronoff G, Brier M
Clin Nephrol
. 2018 Jul;
90(4):276-285.
PMID: 30049300
Background: Standard protocol-based approaches to erythropoiesis stimulating agent (ESA) dosing in anemia management of end-stage renal disease (ESRD) fail to address the inter-individual variability in patient's response to ESA. We...
9.
Mirinejad H, Gaweda A, Brier M, Zurada J, Inanc T
Comput Methods Programs Biomed
. 2017 Aug;
148:45-53.
PMID: 28774438
Background And Objective: Anemia is a common comorbidity in patients with chronic kidney disease (CKD) and is frequently associated with decreased physical component of quality of life, as well as...
10.
Gaweda A
Hemodial Int
. 2017 Mar;
21 Suppl 1:S21-S27.
PMID: 28328097
Anemia is one of the main comorbidities related to chronic kidney disease (CKD). Until the advent of erythropoiesis stimulating agents (ESA), endogenous erythropoietin deficiency has been thought to be the...